IDH1 and glioblastoma: These tumors demonstrate an aggressive clinical course reminiscent of IDH1/2-wild-type glioblastoma, with a median overall survival of 20.4 months in our cohort, similar to that of IDH1/2-wild-type glioblastoma.3 Orthogonal technologies, such as DNA methylation profiling may further distinguish the character of other IDH1/2-wild-type gliomas, with a study demonstrating overlapping methylation signatures of other IDH1/2-wild-type gliomas with IDH1/2-wild-type glioblastomas.34